BriaCell Therapeutics Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.80next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 2026 / Fiscal Year Ended July 31, 2026 Financial Results Release | 15 Oct 2026 |
| Deadline for Shareholder Proposals for Next Annual Meeting | 6 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Pivotal Phase 3 Bria-IMT Trial (BRIA-ABC) Patient Enrollment Quarterly160.0Target: Complete enrollment and reach 144 patient events (deaths) for interim overall survival analysis
Cash, Cash Equivalents, and Short-Term Investments Quarterly22.8MTarget: Secure additional financing to address going concern risk and fund ongoing Phase 3 trials
Watch Items
- Interim Overall Survival (OS) Readout for Phase 3 Bria-IMT TrialTrigger: Occurrence of 144 patient events (deaths)Action: Conduct interim analysis comparing Bria-IMT combination regimen to physician's choice therapy to support potential full FDA approval
- Going Concern Risk and Capital RunwayTrigger: Working capital falling below operational requirements for the next 12 monthsAction: Execute further equity placements, warrant exercises, or strategic partnerships to extend cash runway
- Nasdaq Capital Market Continued Listing ComplianceTrigger: Market Value of Listed Securities (MVLS) below $35,000,000 or closing bid price below $1.00Action: Monitor compliance with Nasdaq Listing Rules 5550(b)(2) and 5550(a)(2) and implement corrective actions if necessary
Research as of 20 Jun 2026